- Home
- AXR vs ATOS Comparison
AXR vs ATOS Comparison
Compare AXR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- ATOS
- Stock Information
- Founded
- AXR 1961
- ATOS 2009
- Country
- AXR United States
- ATOS United States
- Employees
- AXR N/A
- ATOS N/A
- Industry
- AXR Homebuilding
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- AXR Real Estate
- ATOS Health Care
- Exchange
- AXR Nasdaq
- ATOS Nasdaq
- Market Cap
- AXR 114.8M
- ATOS 107.2M
- IPO Year
- AXR N/A
- ATOS 2012
- Fundamental
- Price
- AXR $21.55
- ATOS $0.78
- Analyst Decision
- AXR
- ATOS Strong Buy
- Analyst Count
- AXR 0
- ATOS 3
- Target Price
- AXR N/A
- ATOS $6.17
- AVG Volume (30 Days)
- AXR 9.5K
- ATOS 1.3M
- Earning Date
- AXR 09-12-2025
- ATOS 08-12-2025
- Dividend Yield
- AXR N/A
- ATOS N/A
- EPS Growth
- AXR 89.60
- ATOS N/A
- EPS
- AXR 2.37
- ATOS N/A
- Revenue
- AXR $49,694,000.00
- ATOS N/A
- Revenue This Year
- AXR $124,160.48
- ATOS N/A
- Revenue Next Year
- AXR $8.16
- ATOS N/A
- P/E Ratio
- AXR $9.09
- ATOS N/A
- Revenue Growth
- AXR N/A
- ATOS N/A
- 52 Week Low
- AXR $17.60
- ATOS $0.55
- 52 Week High
- AXR $39.68
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- AXR 43.53
- ATOS 42.24
- Support Level
- AXR $21.94
- ATOS $0.81
- Resistance Level
- AXR $22.65
- ATOS $0.80
- Average True Range (ATR)
- AXR 0.64
- ATOS 0.04
- MACD
- AXR -0.09
- ATOS -0.01
- Stochastic Oscillator
- AXR 2.82
- ATOS 7.50
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.